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ABSTRACT 
Breast cancer is the most common form of cancer affecting women in Malaysia. 
Conventional drug treatment for breast cancer, chemotherapy would destroy the 
cancer cells because of the medicine targets on rapidly dividing cells. However, 
healthy cells and tissues in blood, mouth, intestinal tract, nose, nails, vagina and 
hair also divide rapidly, they could be damaged. A more promising technology 
called transdermal patch has been introduced due to side effects are common 
expected results from conventional treatment. Therefore, the aim of this study was 
to treat breast cancer by delivering drug from transdermal patch precisely and 
safely to targeted cancer cell so that reducing the side effects and dosage of drug 
used. The objectives of this study were to determine the drug concentration at 
breast tumor, to investigate the relationship between drug diffusivity and drug 
delivery efficiency, and to evaluate the efficiency of drug delivery under other 
parameters (i.e. deepness of tumor, temporal and spatial placement of transdermal 
patch). Available software, COMSOL was used in this study. Drug concentrations 
that able to diffuse and reach tumor in breast were studied. The simulation results 
showed that there was optimal drug diffusivity for maximum concentration of drug 
reached tumor in breast. However, below and higher than this drug diffusivity 
optimal value, the delivery of drug concentration was poorer when the lesser. 
Production of microchannels in the skin by microneedle can increase the drug 
diffusivity and ensure delivery of pharmacologically effective concentration of drug 
to the targeted site, breast cancer cell. Deeper the tumor grown within breast, lesser 
drug’s concentration could be diffused to it. However, this could be solved by 
changing the place of transdermal patch application. The nearer the spatial 
placement of transdermal patch to tumor growth in the breast on the breast skin 
increased the effectiveness of drug delivery to tumor. The longer the temporal 
placement resulted in higher drug concentration could be delivered to breast tumor. 
However, this constant concentration gradient only achieved for less than one 
month. After this, the concentration gradient would become zero. As a conclusion, 
the drug diffusivity, deepness of breast tumor, spatial and temporal placement of 
transdermal patch must be taken into account when engineering, constructing and 
applying the transdermal patch in order to achieve the maximum breast cancer 
treatment with reducing the undesired side effects.  
 IX 
ABSTRAK 
 
Kanser payudara merupakan jenis kanser yang paling utama di kalangan wanita di 
Malysia. Ubat rawatan konvensional untuk kanser payudara, kemoterapi akan 
menghancurkan sel-sel kanser kerana ubat target pada sel-sel yang membahagi dengan 
cepat. Namun, sel-sel dan rangkaian yang sihat dalam darah, mulut, saluran, usus 
hidung, kuku, vagina dan rambut juga membelah dengan cepat, mereka boleh 
dirosakkan. Satu teknologi yang lebih menjanjikan disebut patch transdermal telah 
diperkenalkan kerana kesan sampingan merupakan umum hasil daripada rawatan 
konvensional. Oleh itu, tujuan dari penelitian ini adalah untuk mengubati kanser 
payudara dengan menghantarkan ubat dari patch transdermal dengan tepat dan selamat 
pada sel kanser yang disasarkan supaya mengurangkan kesan sampingan dan dosis ubat 
yang digunakan. Objektif-objektif dari penelitian ini adalah untuk menentukan 
konsentrasi ubat pada tumor di payudara, mengkaji perhubungan antara keresapan ubat 
dengan keberkesanan penghantaran ubat, dan menilai keberkesanan penghantaran ubat 
dalam parameter yang berbeza seperti kedalaman tumor dalam payudara, penempatan 
spasial dan temporal patch transdermal pada kulit. Tersedia software, COMSOL 
digunakan dalam kajian ini. Ubat konsentrasi yang dapat menyebar dan mencapai tumor 
dalam payudara dipelajari. Keputusan simulasi menunjukkan bahawa ada ubat 
keresapan optimum untuk konsentrasi ubat maksimum capai pada tumor dalam 
payudara. Namun, di bawah atau di atas nilai keresapan ubat yang optimum ini, 
penghantaran konsentrasi ubat menjadi lemah ketika semakin berkurangan keresapan 
ubat. Produksi microchannels di kulit dengan microneedle dapat meningkatkan 
keresapan ubat dan memastikan penghantaran konsentrasi farmakologi ubat yang 
berkesan ke tempat yang disasarkan, sel kanser payudara. Semakin dalam pertumbuhan 
tumor dalam payudara, semakin berkurangan ubat dapat meresap ke tumor. Namun 
begitu, scenario ini dapat diatasi dengan menukarkan tempat menempatkan patch. 
Semakin dekat penempatan spasial patch transdermal pada pertumbuhan tumor dalam 
payudara pada kulit payudara meningkatkan keberkesanan penghantaran ubat untuk 
tumor. Semakin lama penempatan temporal menghasilkan kepekatan ubat yang boleh 
disampaikan untuk tumor payudara lebih tinggi. Namun, kecerunan konsentrasi ini 
hanya dapat dicapai kurang daripada satu bulan. Selepas ini, kecerunan konsentrasi ubat 
akan menjadi kosong. Sebagai kesimpulan, keresapan ubat, kedalaman pertumbuhan 
tumor dalam payudara, penempatan spasial dan temporal transdermal patch harus 
diperhitungkan sewaktu kejuruteraan, membina dan melaksanakan patch transdermal 
untuk mencapai rawatan kanser payudara maksimum dengan mengurangkan kesan 
sampingan yang tidak diingini. 
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1 INTRODUCTION 
 
 
This chapter presents the overview of the background for disease of breast cancer and 
breast cancer drug therapies. The problem statement of current technology is also stated 
in this chapter. The objectives of the study also presented in this chapter. The scope and 
importance of work are defined. Lastly, this chapter also outlines the organization of the 
thesis.    
 
 
1.1 Background of study 
Breast cancer is the most common form of cancer among women other than other skin 
cancer, and the number of cases for breast cancer is increased annually. About one in 
nineteen women in Malaysia are at risk. Breast cancer is also the leading cause of 
cancer-related death for women. In Peninsula Malaysia, the mortality rate per 100,000 
showed an increase from 3.7 per 100,000 in 1982 to 5.8 per 100,000 in 1990. However, 
since only one-third of deaths in Peninsula Malaysia were medically certified, the 
mortality rate from breast cancer was actually higher. (Yip, C. H. and Ng, E. H., 1996). 
Generally, chemotherapy is the common drug therapy for breast cancer. Many 
anticancer drugs are designed to simply kill cancer cells. They are often in a semi-
specific fashion because the anticancer drugs target on rapidly dividing cells. Similar to 
cancer cells, the normal cells in blood, mouth, intestinal tract, nose, nails, vagina and 
hair also divide rapidly. Consequently, the distribution of anticancer drugs in healthy 
organs or tissues is especially undesirable due to the potential for severe side effects. 
This phenomenon greatly limits the maximal allowable dose of the drugs. However, low 
local drugs‟ concentration will cause less effect on destroying the cancer cells. 
Therefore, there is still a need for high or frequent drugs dosing. 
 To overcome such limitations, a new and more promising technology, transdermal 
technology has been introduced for breast cancer drug therapy. This application 
provides an alternative route for delivering drugs to cancer cells, which is through the 
largest organ of humans‟ bodies, skin. In this method, a transdermal patch is purposely 
engineered and constructed to allow the delivering of drugs precisely to the targeted 
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cancer cells with fewer side effects. Site-specific drugs delivery is a concept that has the 
potential to increase local drugs‟ concentrations, and thereby produce more effective 
medicines with reducing the dosage of drugs used. 
 
1.2 Problem statement 
The new technology, transdermal patch allows the delivering of anticancer drugs to 
targeted cancer cell as effectively as possible without side effects and reducing the 
dosage of drugs used. However, transdermal application has limitation due to the 
remarkable barrier properties of the outermost layer of skin, stratum corneum. This 
layer is mainly consisted of lipids, has no blood flow, and thus plays a key role in 
limiting the diffusion of drugs to the bloodstream. For transdermal drugs delivery 
system to be effective, the drugs must obviously be able to penetrate this skin barrier 
and reach the targeted cancer cells. To achieve this, suitable modification has been 
made on the transdermal delivery system. It is hard to deny that drug diffusivity is a 
very important factor to be considered.  
 
1.3 Objectives 
The aim of this study was to treat breast cancer by delivering drug from transdermal 
patch precisely to targeted cancer cells so that reducing the side effects and dosage of 
drugs used. This can be achieved by the following specific objectives: 
1. To convert Materilaise's Interactive Medical Image Control System 
(MIMICS) image   files into comsol, 
2. To determine the drug concentration at breast tumor 
3. To investigate the relationship between drug diffusivity and drug delivery 
efficiency, and 
4. To evaluate the efficiency of drug delivery under other parameters (i.e. 
deepness of tumor, temporal and spatial placement of transdermal patch). 
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1.4 Research scope 
This study mainly focused on the efficiency of drug delivery from transdermal patch, 
which was evaluated by response parameter, drug concentration successfully reaching at 
the breast tumor. The study was carried out by using COMSOL software. Before 
implementing the COMSOL software, data collection for drug diffusivity and breast 
volume were needed. After data collection, Materilaise's Interactive Medical Image 
Control System (MIMICS) image   files where converted by using COMSOL software. 
After converting the image files, simulation was run by using COMSOL software. The 
simulation was conducted with identified independent variables (i.e. drug diffusivity, 
deepness of tumor, temporal and spatial placement of transdermal patch). Simulation 
produced with different parameters was saved for further analyses. Graphs that relate 
the drug concentration at breast tumor were also developed. From the developed graphs, 
the association between the efficiency of drug delivery and drug concentration could be 
made.  
 
 
1.5 Rationales and significances 
This study had the significance to do a new strategy on developing a more promising 
technology to treat breast cancer. This study also important for eliminate the side effects 
or toxicities caused by conventional drug therapies. This was replaced by the 
application of new technology, transdermal patch. The other significance was including 
reducing the drug dosage used for breast cancer treatment. Reduce side effects and drug 
dosage used, thereby decreasing the cost of breast cancer treatment. 
 
 
1.6 Organization of thesis   
This thesis is mainly delegated into five different chapters. In first chapter, the 
background of study, problem statement, objectives, scope and significances of project 
are reviewed in order to list out the tasks and act as a guideline for this study. The 
statistic of breast cancer, skin structure, theoretical background, previous studies and 
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some basic information related to the project title are detailed in the second chapter. 
Chapter 3 presents the methodology used from the starting until the end of the study, 
which including the material or instrument used for completing the study, designing the 
simulation and how to run the simulation. An overview of overall methodology that 
designated in a flow chart as guideline for task sequences also included in this chapter. 
 
Chapter 4 shows the results obtained from the simulation. Several graphs made to 
preview the relationship between the drug concentration and time, which were resulting 
from different parameters also presented. At the end of this chapter, results, some of 
findings and the sources of errors that affect the simulation outcomes are discussed in 
details. The last chapter, chapter 5 states the conclusions of the study. 
Recommendations for improvement of the study in the future also are outlined in this 
chapter.  
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2 LITERATURE REVIEW 
 
This chapter includes the statistic of breast cancer, drug therapies of breast cancer, 
structure of skin, theories of transdermal application and some basic information related 
to the study. Studies on some recent patents related to the field of transdermal patch are 
also presented.  
 
 
2.1 Overview of breast cancer statistic  
The problem of cancer in Malaysia is in a growing trend, and breast cancer is the most 
common cancer among women. Over the years from 1993 to 2003, there were a total of 
1818 breast cancer patients in the University Hospital. The number of breast cancer 
patients increased annually, with the highest recorded in 2003. This was 6 times the 
number of breast cancer patients in 1993 (Figure 2.1).              
 
 
 
 
 
 
 
Figure 2.1: Breast cancer in University Malaya Medical Centre, Kuala Lumpur 
          1993-2003, with total number of 1818 cases. 
 
Source: College Of Radiology Breast Health Information Centre (2008) 
 
 
 
 
 
Breast cancer formed 30% and 31.1% of newly diagnosed cancer cases in women in 
2002 and 2003. This was followed by cancer of the cervix, which only formed 12% and 
12.9% of total female cancers in 2003 and 2003 respectively (Figure 2.2). 
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Figure 2.2: Percentage of different kinds of cancer in Malaysian women, in the 
year      
        of 2002 and 2003. 
 
Source: College Of Radiology Breast Health Information Centre (2008) 
 
The number of deaths form breast cancer also showed an increasing trend, which were 
260, 320 and 339 for the year of 1994, 1995 and 1998 respectively. And within these 
numbers, only 1/3 of all deaths in Malaysia were medically certified (Table 2.1). This 
indicated that the awareness of breast cancer among women still low and not effective 
enough. Within the detected women with breast cancer, only 55.6% of Malaysian 
women presented with early stage breast cancer (Stage 0 – 1) compared with 72% of 
Singaporean women in 1990. (Yip, C. H. and Ng, E. H., 1996) From the year of 1993 to 
2004, there were 30-40% of the patients presented in the late stage and although women 
are now presenting with smaller tumours, the decrease in size is not significant. 
(College Of Radiology Breast Health Information Centre, 2008). 
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Table 2.1: Deaths from cancers in Malaysia women for the years of 1994, 1995 and 
       1998 
            
 
  
 
 
 
 
 
 
 
 
 
 Source: Vital Statistic Malaysia 
 
 
2.2 Conventional breast cancer drug therapy 
The most common breast cancer drug therapy, also known as chemotherapy, in simplest 
sense, is a treatment with the aid of drugs that killing microorganisms or cancerous 
cells. The chemotherapy drugs can be swallowed by someone as tablets or capsules, or 
injected intravenously through the veins. When the drugs reach cancer cells, the drugs 
work by disrupting the growth of cancer cells.  
However, when the drugs circulate in the blood, they not only reach cancer cells, but 
wherever they are in body. Many anticancer drugs are designed simply kill cancer cells. 
They have no the capability to distinguish between the cancer cells and normal cells. In 
contrast, they work by killing the cells that are actively growing and dividing into new 
cells.  Cancer cells do grow and divide much more often than normal cells because most 
normal cells grow and divide in a precise, orderly way.  Thus, cancer cells are more 
likely to be killed by the chemotherapy drugs. However, there are still some normal 
cells do divide and grow rapidly such as cells in hair follicles, nails, mouth, intestinal 
tract and bone marrow. Chemotherapy drugs can unintentionally harm these other types 
of rapidly dividing cells. As a result, the distribution of anticancer drugs in healthy and 
normal cells is especially undesirable due to the potential for severe side effects.    
 The side effects caused are significantly depending on the types of drugs, drugs dosage 
used, how long the drugs are taken and how though of the own body of the one who 
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consuming these chemotherapy drugs. The possibilities of common side effects caused 
by some different kinds of anticancer drugs are discussed with details in the next sub-
topic. 
 
2.2.1    Docetaxel  
Docetaxel is one of the taxane drugs that were originally developed from the yew tree. 
Docetaxel is a man-made drug that was first made from the needles of the yew tree. It is 
known by its brand name, Taxotere. It works by stopping the cancer cells from 
separating into two new cells, so it blocks the growth of the cancer. Common side 
effects caused by this drug are as following (Cancer Health UK, 2009):- 
 Have temporary drop in the number of blood cells made by the bone marrow. 
For example, a drop in white blood cells result a person with increased risk of 
getting an infection. When there is a dropping of red blood cells, a person will 
easy feel tired and breathless. Besides, bruising easily is another common side 
effect due to a drop in platelets.  
 Fatigue is the most disruptive side effect where tiredness often carries on after 
treatment has just ended. 
 Patients may experience fluid retention such as swelling of the hands and feet 
and resulting in weight gain and breathless. 
 Some people develop soreness, redness and peeling on the palms of the hands 
and soles of the feet. 
 Patients may have rash, hair loss, sore mouth, diarrhoe, numbness and tingling in 
hands and feets, allergic reaction during the infusion and fingernails become 
discoloured. 
 Docetaxel may have a harmful effect on a baby developing in the womb.  
 
2.2.2 Doxorubicin (adriamycin) 
Doxorubicin works by binding to the cancer cells‟ DNA and blocking an important 
enzyme called topo-isomerase II. This makes the DNA get tangled up and the cancer 
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cells cannot divide and grow. The common side effects associated with doxorubicin are 
listed below (Cancer Health UK, 2009):- 
 Have temporary drop in the number of blood cells made by the bone marrow. 
For example, a drop in white blood cells result a person with increased risk of 
getting an infection. When there is a dropping of red blood cells, a person will 
easy feel tired and breathless. Besides, bruising easily is another common side 
effect due to a drop in platelets.  
 Fatigue during and after treatment. 
 Feeling or being sick may be severe. 
 Urine may become a pink or red colour for one or two days after treatment. 
 Patients may have hair loss, sore mouth, sensitivity to sunlight, black or brown 
lines may appear in the creases of skin, watery eyes and conjunctivitis but very 
rare to happen. 
 A woman may stop or temporarily stop having periods, and loss of fertility. 
 Doxorubicin may have a harmful effect on a developing baby.  
 
2.2.3 Herceptin (trastuzumab) 
Herceptin is a monoclonal antibody. It targets a protein called HER2. This protein is 
found in roughly 25 to 30 percent of breast cancers. By interfering with this protein, this 
medicine can stop cancer cell growth. With this drug, the common side effects are:- 
 Breathing difficulties. 
 Chest pain or palpitations. 
 Cough. 
 Dizziness or fainting. 
 Fever or chills, sore throat. 
 Skin rash, itching or hives. 
 Swelling of the legs or ankles. 
 Usually weak or tired. 
 Loss of appetite. 
 Headache. 
 Muscle aches. 
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2.2.4 Paclitaxel (taxol) 
Paclitaxel is in a class of drugs known as taxanes. It slows or stops the growth of cancer 
cells in body. Side effects from paclitaxel are common, and include:- 
 
 Nausea and vomiting. 
 Loss of appetite. 
 Change in taste. 
 Thinned or brittle hair. 
 Pain in the joints of the arms or legs lasting 2-3 days. 
 Changes in the colour of the nails. 
 Tingling in the hands or toes. 
 
 
2.2.5 Methorexate (maxtrex) 
Methotrexate is similar to a normal body molecule called folinic acid, but has a slightly 
different in structure. So it stops some cells working properly. Cancer cells need to 
make and repair DNA to grow and multiply. Anti-metabolites often stop cells making 
and repairing DNA. Methotrexate also stops some normal cells working properly, 
causing side effects as following (Cancer Health UK, 2009):- 
 Have temporary drop in the number of blood cells made by the bone 
marrow. For example, a drop in white blood cells result a person with 
increased risk of getting an infection. When there is a dropping of red 
blood cells, a person will easy feel tired and breathless. Besides, 
bruising easily is another common side effect due to a drop in platelets.  
 Fatigue during and after treatment. 
 A patient may experience taste changes, mouth sores, diarrhoe, gritty 
eyes and hair loss or hair thinning. 
 This drug may harm a baby developing in the womb. 
 
Besides of individual chemotherapy drugs, there are some chemotherapy combinations 
of drugs used for killing cancer cells such as doxorubicin and cyclophosphamide (AC), 
methotrexate, mitozantrone and mitomycin (MMM), epirubicin, cyclophosphamide and 
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fluoruocil (FEC) and the list goes on. These combinations are kwon as combination 
regimens and different combinations of drugs have different side effects. 
 
2.3 Materilaise's interactive medical image control system  (MIMICS) 
Materilaise's Interactive Medical Image Control System (MIMICS) is an interactive 
toolbox for the visualization and segmentation of stacked images (CT, microCT, 
MRI,…) and 3D rendering of objects. It provides the users the tools to convert the 
images to 3D objects and prepare these objects for different application domains.  
Mimics Software is developed by Materialise NV a Belgian company that is specialized 
in additive manufacturing software and technology. Nowadays, engineers are playing a 
crucial role by supporting doctors and improving the quality of life of patients through 
optimized implants and devices, scientifically validated surgical procedures, studying 
surgical simulation, and more. Together, these Engineering professionals are working 
towards a better and healthier world. 
 
Mimics offers the following services as shown in Figure : 
 
1. DICOM to 3D 
2. 3D to CAD 
3. 3D analysis 
4. Medical models 
5. FEA/CFD modeling 
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Figure 2.3: Process of converting in Mimics. 
 
Source: application of ddm in medical implant 
 
 
Mimics most involvement is in the biomedical engineering area and it's a purpose for 
research and development in various medical specializations such as: 
 Orthopedic. 
 Cranio-maxillofacial. 
 Cardiovascular. 
 Pulmonology. 
 Dentistry. 
 Orthoses & Prostheses. 
 
As such Mimics provides a link between stacked images and the following: 
• Rapid prototyping. 
• Visualization. 
• Finite element analysis. 
• Computational fluid dynamics. 
• Computer aided design. 
• Surgical simulation. 
• Porous structures analysis. 
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Mimics modules: 
Mimics consist of six modules, the links between the base program, the modules and 
the main application areas as shown in figure 2.4 
 
 
Figure 2.4 : Mimics six modules 
Source: application of ddm in medical implant 
 
 
2.4 Comsol 
 
2.4.1 Introduction 
COMSOL is all about flexible platform that allows even novice users to model all relevant 
physical aspects of their designs. Advanced users can go deeper and use their knowledge 
to develop customized solutions, applicable to their unique circumstances. With this kind 
of all-inclusive modeling environment, COMSOL gives us the confidence to build the 
model we want with real-world precision. 
